Systematic review of β-elemene injection as adjunctive treatment for lung cancer / 中国结合医学杂志
Chinese journal of integrative medicine
;
(12): 813-823, 2012.
Article
in English
| WPRIM
| ID: wpr-347107
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the effectiveness and safety of β-elemene Injection as an adjunctive treatment for lung cancer by systematic review.</p><p><b>METHODS</b>We retrieved randomized controlled clinical trials related to the use of β-elemene Injection as an adjunctive treatment for lung cancer from Chinese Biomedical (CBMweb), Chinese Medical Current Content (CMCC), China National Knowledge Infrastructure (CNKI), ChinaInfo, Cochrane Central Register of Controlled Trials; MEDLINE, EMBASE, OVID and TCMLARS. We also referred to an unpublished conference proceeding titled Clinical Use and Basic Elemene Injection. We then divided the studies into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) subgroups by RevMan 5.1 software.</p><p><b>RESULTS</b>A total of 21 source documents (1,467 patients) matched pre-specified criteria for determining the effectiveness and safety of β-elemene Injection as an adjunctive treatment for lung cancer. Five studies involving 285 NSCLC patients reported a higher 24-month survival rate (39.09%) with the adjunctive treatment than with chemotherapy alone (26.17%; RR, 1.51; 95% CI, 1.03 to 2.21). Four studies involving 445 patients reported that the increased probability for improved performance status for patients treated with elemene-based combinations was higher than that of patients treated with chemotherapy alone (RR, 1.82; 95% CI, 1.45 to 2.29). The results from a subgroup analysis on 12 studies involving 974 NSCLC patients and 9 studies involving 593 patients with both SCLC and NSCLC showed that the tumor control rate for NSCLC improved more in the elemene-based combinations treatment group (78.70%) than in the chemotherapy alone control group (71.31%; RR, 1.06; 95% CI, 1.00 to 1.12). The tumor response rate for NSCLC also improved more among patients treated with elemenebased combinations (50.71%) than among patients treated with chemotherapy alone (38.04%; RR, 1.34; 95%CI, 1.17 to 1.54). In addition, the main adverse reaction to β-elemene Injection was phlebitis, but usually only to a mild degree. An Egger's test showed no publication bias in our study (P=0.7030).</p><p><b>CONCLUSIONS</b>The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined with β-elemene injection as an adjunctive treatment. The combined treatment can result in an improved quality of life and prolonged survival. However, these results require confirmation by rigorously controlled trials.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sesquiterpenes
/
Drugs, Chinese Herbal
/
Epidemiology
/
Chemotherapy, Adjuvant
/
Combined Modality Therapy
/
Carcinoma, Non-Small-Cell Lung
/
Drug Therapy
/
Small Cell Lung Carcinoma
/
Injections
/
Lung Neoplasms
Type of study:
Controlled clinical trial
/
Systematic reviews
Limits:
Humans
Language:
English
Journal:
Chinese journal of integrative medicine
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS